{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:34:20Z","timestamp":1781710460648,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The in vitro interactions of isavuconazole with colistin were evaluated against 15 clinical <jats:italic>Candida auris<\/jats:italic> isolates by a microdilution checkerboard technique based on the EUCAST reference method for antifungal susceptibility testing and by agar diffusion using isavuconazole gradient concentration strips with or without colistin incorporated RPMI agar. Interpretation of the checkerboard results was done by the fractional inhibitory concentration index and by response surface analysis based on the Bliss model. By checkerboard, combination was synergistic for 93% of the isolates when interpretation of the data was done by fractional inhibitory concentration index, and for 80% of the isolates by response surface analysis interpretation. By agar diffusion test, although all MICs in combination decreased compared to isavuconazole alone, only 13% of the isolates met the definition of synergy. Essential agreement of EUCAST and gradient concentration strip MICs at\u2009+\/\u2212 2 log<jats:sub>2<\/jats:sub> dilutions was 93.3%. Antagonistic interactions were never observed for any technique or interpretation model used.<\/jats:p>","DOI":"10.1038\/s41598-020-78588-5","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T11:04:42Z","timestamp":1607425482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["In vitro synergy of isavuconazole in combination with colistin against Candida auris"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-1865","authenticated-orcid":false,"given":"Patrick","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Bidaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-3830","authenticated-orcid":false,"given":"Eric","family":"Dannaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"78588_CR1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00029-17","author":"A Jeffery-Smith","year":"2018","unstructured":"Jeffery-Smith, A. et al. Candida auris: a review of the literature. Clin. Microbiol. Rev. https:\/\/doi.org\/10.1128\/CMR.00029-17 (2018).","journal-title":"Clin. Microbiol. Rev."},{"key":"78588_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/myc.12904","volume":"62","author":"SA Lone","year":"2019","unstructured":"Lone, S. A. & Ahmad, A. Candida auris\u2014the growing menace to global health. Mycoses 62, 620\u2013637. https:\/\/doi.org\/10.1111\/myc.12904 (2019).","journal-title":"Mycoses"},{"key":"78588_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01588-17","author":"ES Spivak","year":"2018","unstructured":"Spivak, E. S. & Hanson, K. E. Candida auris: an emerging fungal pathogen. J. Clin. Microbiol. https:\/\/doi.org\/10.1128\/JCM.01588-17 (2018).","journal-title":"J. Clin. Microbiol."},{"key":"78588_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1348-0421.2008.00083.x","volume":"53","author":"K Satoh","year":"2009","unstructured":"Satoh, K. et al. Candida auris sp. Nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol. 53, 41\u201344. https:\/\/doi.org\/10.1111\/j.1348-0421.2008.00083.x (2009).","journal-title":"Microbiol. Immunol."},{"key":"78588_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.mycmed.2018.06.007","volume":"28","author":"AL Bidaud","year":"2018","unstructured":"Bidaud, A. L., Chowdhary, A. & Dannaoui, E. Candida auris: an emerging drug resistant yeast\u2014a mini-review. J. Mycol. Med. 28, 568\u2013573. https:\/\/doi.org\/10.1016\/j.mycmed.2018.06.007 (2018).","journal-title":"J. Mycol. Med."},{"key":"78588_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dkx480","volume":"73","author":"A Chowdhary","year":"2018","unstructured":"Chowdhary, A. et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009\u201317) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J. Antimicrob. Chemother. 73, 891\u2013899. https:\/\/doi.org\/10.1093\/jac\/dkx480 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"78588_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/cid\/ciw691","volume":"64","author":"SR Lockhart","year":"2017","unstructured":"Lockhart, S. R. et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. 64, 134\u2013140. https:\/\/doi.org\/10.1093\/cid\/ciw691 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"78588_CR8","doi-asserted-by":"publisher","first-page":"e00578","DOI":"10.1002\/mbo3.578","volume":"7","author":"J Osei Sekyere","year":"2018","unstructured":"Osei Sekyere, J. Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen 7, e00578. https:\/\/doi.org\/10.1002\/mbo3.578 (2018).","journal-title":"Microbiologyopen"},{"key":"78588_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1385\/1-59259-943-5:143","volume":"118","author":"RG Vitale","year":"2005","unstructured":"Vitale, R. G., Afeltra, J. & Dannaoui, E. Antifungal combinations. Methods Mol. Med. 118, 143\u2013152. https:\/\/doi.org\/10.1385\/1-59259-943-5:143 (2005).","journal-title":"Methods Mol. Med."},{"key":"78588_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01393-19","author":"AL Bidaud","year":"2019","unstructured":"Bidaud, A. L., Botterel, F., Chowdhary, A. & Dannaoui, E. In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01393-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78588_CR11","doi-asserted-by":"publisher","first-page":"105901","DOI":"10.1016\/j.ijantimicag.2020.105901","volume":"55","author":"AL Bidaud","year":"2020","unstructured":"Bidaud, A. L., Djenontin, E., Botterel, F., Chowdhary, A. & Dannaoui, E. Colistin interacts synergistically with echinocandins against Candida auris. Int. J. Antimicrob. Agents 55, 105901. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105901 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"78588_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01056-17","author":"H Fakhim","year":"2017","unstructured":"Fakhim, H. et al. In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01056-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78588_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02195-19","author":"B O'Brien","year":"2020","unstructured":"O\u2019Brien, B., Chaturvedi, S. & Chaturvedi, V. In vitro evaluation of antifungal drug combinations against multidrug-resistant Candida auris isolates from New York outbreak. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02195-19 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78588_CR14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s40262-017-0561-1","volume":"56","author":"N Gregoire","year":"2017","unstructured":"Gregoire, N., Aranzana-Climent, V., Magreault, S., Marchand, S. & Couet, W. Clinical pharmacokinetics and pharmacodynamics of colistin. Clin. Pharmacokinet. 56, 1441\u20131460. https:\/\/doi.org\/10.1007\/s40262-017-0561-1 (2017).","journal-title":"Clin. Pharmacokinet."},{"key":"78588_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00873-18","author":"T Brennan-Krohn","year":"2018","unstructured":"Brennan-Krohn, T., Pironti, A. & Kirby, J. E. Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00873-18 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78588_CR16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1128\/AAC.00956-09","volume":"54","author":"R Ben-Ami","year":"2010","unstructured":"Ben-Ami, R., Lewis, R. E., Tarrand, J., Leventakos, K. & Kontoyiannis, D. P. Antifungal activity of colistin against Mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob. Agents Chemother. 54, 484\u2013490. https:\/\/doi.org\/10.1128\/AAC.00956-09 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78588_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13756-019-0521-7","volume":"8","author":"H Yousfi","year":"2019","unstructured":"Yousfi, H., Ranque, S., Rolain, J. M. & Bittar, F. In vitro polymyxin activity against clinical multidrug-resistant fungi. Antimicrob. Resist. Infect. Control 8, 66. https:\/\/doi.org\/10.1186\/s13756-019-0521-7 (2019).","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"78588_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s10096-013-1850-8","volume":"32","author":"DM MacCallum","year":"2013","unstructured":"MacCallum, D. M., Desbois, A. P. & Coote, P. J. Enhanced efficacy of synergistic combinations of antimicrobial peptides with caspofungin versus Candida albicans in insect and murine models of systemic infection. Eur. J. Clin. Microbiol. Infect. Dis. 32, 1055\u20131062. https:\/\/doi.org\/10.1007\/s10096-013-1850-8 (2013).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"78588_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/myc.12022","volume":"56","author":"H Schemuth","year":"2013","unstructured":"Schemuth, H. et al. In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. Mycoses 56, 297\u2013303. https:\/\/doi.org\/10.1111\/myc.12022 (2013).","journal-title":"Mycoses"},{"key":"78588_CR20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3389\/fmicb.2016.01439","volume":"7","author":"R Teixeira-Santos","year":"2016","unstructured":"Teixeira-Santos, R. et al. Unveiling the synergistic interaction between liposomal amphotericin B and colistin. Front. Microbiol. 7, 1439. https:\/\/doi.org\/10.3389\/fmicb.2016.01439 (2016).","journal-title":"Front. Microbiol."},{"key":"78588_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/jac\/dks538","volume":"68","author":"U Zeidler","year":"2013","unstructured":"Zeidler, U. et al. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J. Antimicrob. Chemother. 68, 1285\u20131296. https:\/\/doi.org\/10.1093\/jac\/dks538 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"78588_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/IDR.S102207","volume":"9","author":"SK Natesan","year":"2016","unstructured":"Natesan, S. K. & Chandrasekar, P. H. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect. Drug Resist. 9, 291\u2013300. https:\/\/doi.org\/10.2147\/IDR.S102207 (2016).","journal-title":"Infect. Drug Resist."},{"key":"78588_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00485-17","author":"MC Arendrup","year":"2017","unstructured":"Arendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C. & Chowdhary, A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00485-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78588_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ijantimicag.2019.02.005","volume":"53","author":"AC Ruiz-Gaitan","year":"2019","unstructured":"Ruiz-Gaitan, A. C., Canton, E., Fernandez-Rivero, M. E., Ramirez, P. & Peman, J. Outbreak of Candida auris in Spain: a comparison of antifungal activity by three methods with published data. Int. J. Antimicrob. Agents 53, 541\u2013546. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.02.005 (2019).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"78588_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017 (2020).","journal-title":"N. Engl. J. Med."},{"key":"78588_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","author":"JM Sanders","year":"2019","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease (COVID-19): a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.6019 (2019).","journal-title":"JAMA"},{"key":"78588_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01169","author":"JP Hussman","year":"2020","unstructured":"Hussman, J. P. Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2020.01169 (2020).","journal-title":"Front. Pharmacol."},{"key":"78588_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"78588_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fmicb.2019.00041","volume":"10","author":"A Miro-Canturri","year":"2019","unstructured":"Miro-Canturri, A., Ayerbe-Algaba, R. & Smani, Y. Drug repurposing for the treatment of bacterial and fungal infections. Front. Microbiol. 10, 41. https:\/\/doi.org\/10.3389\/fmicb.2019.00041 (2019).","journal-title":"Front. Microbiol."},{"key":"78588_CR30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1164\/ajrccm.149.5.8173779","volume":"149","author":"JB Bass Jr","year":"1994","unstructured":"Bass, J. B. Jr. et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 149, 1359\u20131374. https:\/\/doi.org\/10.1164\/ajrccm.149.5.8173779 (1994).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78588_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12909","author":"P Schwarz","year":"2019","unstructured":"Schwarz, P., Cornely, O. A. & Dannaoui, E. Antifungal combinations in Mucorales: a microbiological perspective. Mycoses https:\/\/doi.org\/10.1111\/myc.12909 (2019).","journal-title":"Mycoses"},{"key":"78588_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jof6030103","author":"P Schwarz","year":"2020","unstructured":"Schwarz, P. & Dannaoui, E. In vitro interaction between isavuconazole and tacrolimus, cyclosporin A, or sirolimus against Aspergillus Species. J. Fungi (Basel). https:\/\/doi.org\/10.3390\/jof6030103 (2020).","journal-title":"J. Fungi (Basel)"},{"key":"78588_CR33","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/jac\/dkz102","volume":"74","author":"P Schwarz","year":"2019","unstructured":"Schwarz, P., Schwarz, P. V., Felske-Zech, H. & Dannaoui, E. In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales. J. Antimicrob. Chemother. 74, 1921\u20131927. https:\/\/doi.org\/10.1093\/jac\/dkz102 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"78588_CR34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jgar.2020.01.002","volume":"21","author":"H Yousfi","year":"2020","unstructured":"Yousfi, H., Ranque, S., Cassagne, C., Rolain, J. M. & Bittar, F. Identification of repositionable drugs with novel antimycotic activity by screening the Prestwick Chemical Library against emerging invasive moulds. J. Glob. Antimicrob. Resist. 21, 314\u2013317. https:\/\/doi.org\/10.1016\/j.jgar.2020.01.002 (2020).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"78588_CR35","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","volume":"30","author":"LM Lim","year":"2010","unstructured":"Lim, L. M. et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30, 1279\u20131291. https:\/\/doi.org\/10.1592\/phco.30.12.1279 (2010).","journal-title":"Pharmacotherapy"},{"key":"78588_CR36","unstructured":"Arendrup, M. C. et al. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts (EUCAST definitive document E.Def 7.3.2) (2020)."},{"key":"78588_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","volume":"14","author":"MN Prichard","year":"1990","unstructured":"Prichard, M. N. & Shipman, C. Jr. A three-dimensional model to analyze drug\u2013drug interactions. Antiviral Res. 14, 181\u2013205 (1990).","journal-title":"Antiviral Res."},{"key":"78588_CR38","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli, G. Y. et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32, 2866\u20132868. https:\/\/doi.org\/10.1093\/bioinformatics\/btw230 (2016).","journal-title":"Bioinformatics"},{"key":"78588_CR39","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1128\/AAC.46.9.2982-2989.2002","volume":"46","author":"DTA Te Dorsthorst","year":"2002","unstructured":"Te Dorsthorst, D. T. A. et al. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob. Agents Chemother. 46, 2982\u20132989 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78588_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/00912700122010537","volume":"41","author":"MD Reed","year":"2001","unstructured":"Reed, M. D., Stern, R. C., O\u2019Riordan, M. A. & Blumer, J. L. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41, 645\u2013654. https:\/\/doi.org\/10.1177\/00912700122010537 (2001).","journal-title":"J. Clin. Pharmacol."},{"key":"78588_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2110-5820-1-14","volume":"1","author":"H Spapen","year":"2011","unstructured":"Spapen, H., Jacobs, R., Van Gorp, V., Troubleyn, J. & Honore, P. M. Renal and neurological side effects of colistin in critically ill patients. Ann. Intensive Care 1, 14. https:\/\/doi.org\/10.1186\/2110-5820-1-14 (2011).","journal-title":"Ann. Intensive Care"},{"key":"78588_CR42","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/AAC.01733-10","volume":"55","author":"SM Garonzik","year":"2011","unstructured":"Garonzik, S. M. et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55, 3284\u20133294. https:\/\/doi.org\/10.1128\/AAC.01733-10 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78588_CR43","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1128\/AAC.00990-07","volume":"52","author":"DP Kontoyiannis","year":"2008","unstructured":"Kontoyiannis, D. P. et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob. Agents Chemother. 52, 735\u2013738. https:\/\/doi.org\/10.1128\/AAC.00990-07 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78588_CR44","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1128\/JCM.02248-12","volume":"50","author":"E Cendejas-Bueno","year":"2012","unstructured":"Cendejas-Bueno, E. et al. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J. Clin. Microbiol. 50, 3641\u20133651 (2012).","journal-title":"J. Clin. Microbiol."},{"key":"78588_CR45","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3201\/eid1910.130393","volume":"19","author":"A Chowdhary","year":"2013","unstructured":"Chowdhary, A. et al. New clonal strain of Candida auris, Delhi, India. Emerg. Infect. Dis. 19, 1670\u20131673 (2013).","journal-title":"Emerg. Infect. Dis."},{"key":"78588_CR46","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1086\/597108","volume":"48","author":"M-N Kim","year":"2009","unstructured":"Kim, M.-N. et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 48, e57-61 (2009).","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"78588_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52, 1. https:\/\/doi.org\/10.1093\/jac\/dkg301 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"78588_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.09.003","author":"RG Otto","year":"2018","unstructured":"Otto, R. G. et al. An alternative strategy for combination therapy: interactions between polymyxin B and non-antibiotics. Int. J. Antimicrob. Agents https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.09.003 (2018).","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78588-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78588-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78588-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:22:54Z","timestamp":1670372574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78588-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78588"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78588-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patrick Schwarz has received research grants from Basilea Pharmaceutica, Gilead and Pfizer and received travel grants from Gilead and Pfizer. During the past 5\u00a0years, Eric Dannaoui has received research grants from MSD and Gilead; travel grants from Gilead, MSD, Pfizer, and Astellas, and speaker\u2019s fee from Gilead, MSD, and Astellas. Anne-Laure Bidaud has none to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21448"}}